OBJECTIVE: To summarize and evaluate the literatureregarding the clinical features, epidemiology,etiology, pathophysiology,and treatment of infantile spasms.
Thisarticleis approved for continuing education credit Few well-designed, prospective,controlled clinical trials for the treatment of infantilespasms have been conducted. CONCLUSIONS: Standard anticonvulsants such as phenytoin, the barbiturates, carbamazepine,and the succinimideshave been ineffective. Of the anticonvulsants, only the benzodiazepines, valproic acid, and vigabatrinhave shown efficacy in reducing spasm frequency and severity. Hormonal therapy with adrenocorticotropic hormone (ACTH) and/or prednisone has been the most frequently studied treatment modality and appears to be the most effective. Hormonal therapy achieves complete spasm control in 5(}-75 percent of infants within four weeks of initiation. Opinions differ regarding the relative efficacy between ACTH and prednisone,the need for early initiationof hormonal treatment,and the benefitsof high dosages of ACTH (>40 units/d). No treatmenthas been shown conclusively to improve the long-term intellectual developmentof these infants. Neurosurgerymay be the treatmentof choice in select cases when a localizedcentral nervous system abnormalitycan be demonstrated.Well-designed, blind, prospectiveclinical trials are needed to answer definitively many lingeringquestionsregardingthe treatmentof infantile spasms.
Ann Phannacother 1994;28:779-9 I. INFANTILE SPASMS were ftrst described in 1841 by West, who observed this rare epileptic phenomenon in his own son.I Classifted as a generalized epileptic syndrome, this often devastating malady has also been called jack-knife convulsions, massive myoclonic seizures, cheerleader spasms, infantile myoclonic seizures, Blitz-Nick-Salaam-Krompfe, lightning seizures, and salaam attacks.>' The majority of patients with infantile spasms have some degree of developmental retardation.Y An abnormal electroencephalographic (EEG) pattern, termed hypsarrhythmia, frequently is associated with this disorder," The triad of infantile spasms, mental retardation, and hypsarrhythrnia is known as West's syndrome.
The optimal treatment of infantile spasms remains controversial. Standard anticonvulsants have had little effect on seizure frequency or severity and have not averted the long-term sequelae of the disorder. Although hormonal treatment was shown to abolish spasms in most infants as early as 1958,8 no consensus as to the drug of choice, optimal dosage, duration, urgency, or long-term benefits of treatment exists today."
Clinical Features
Infantile spasms are characterized by a brief, symmetric contraction of the muscles of the neck, trunk, and/or extremities. Most cases of infantile spasms involve a mix of extensor and flexor muscles (42 percent), but may involve only flexor (34 percent) or only extensor (22 percent) muscles." The spasms may be a massive contraction of multiple muscle groups or an isolated muscle group, and may vary depending on the infant's body position. The flexortype spasm often involves contraction of abdominal muscles, resulting in flexion at the waist to produce a characteristic jack-knife contortion of the body. If seated, the child's upper body may be thrown forward, resembling a respectful salaam greeting. Extensor spasms may result in the arching of the back and extension of the limbs, resembling a cheerleader waving pom-poms. Mixed spasms result from simultaneous extension and flexion of various muscle groups, but are nearly always bilaterally symmetric. If the spasm is limited to the neck muscles, a characteristic head bob may be the only manifestation of the disorder. Eye movements also commonly occur during a spasm, consisting of deviation or nystagmus. Alteration in respiration is common as well.3.4·lo-I2 Each spasm may be followed by a brief tonic phase of up to a few seconds, during which the flexed and/or extended body position is maintained. Spasms generally occur in a series of at least 2 to more than 100 during one episode, termed a cluster or flurry. During a cluster, the infant may experience as many as 15 spasms/min, with spasms generally occurring at a definite cadence. The intensity of the spasms often waxes and wanes during a flurry. These episodes commonly occur immediately or soon after arousal, rarely while the infant is asleep. Spasms may be provoked in some infants by an unexpected stimulus, such as a loud noise. The spasms are not precipitated by feeding or stimulation with Iight. 3 
.4.lo-I2
It may be difficult by visual observation alone to distinguish infantile spasms from other normal and abnormal infant behaviors." A number of syndromes may imitate the clinical manifestations of infantile spasms, including myoclonic seizures, nonepileptic myoclonus, spasticity, colic, and gastroesophageal reflux. The concurrent presence of infantile spasm imitators in a patient with true infantile spasms may obscure the diagnosis or the assessment of treatment efficacy. Therefore, video-EEG monitoring has been recommended as the most appropriate tool to evaluate patients and to document persistent spasm activity after initiation of drug therapy."
The classic EEG abnormality closely associated with infantile spasms is the hypsarrhythmia, described by Gibbs and Gibbs in 1952 .' Hypsarrhythmia is a highly dynamic and chaotic EEG pattern, characterized by random highvoltage slow waves and spikes, which vary from moment to moment in location and duration. The hypsarrhythmic pattern is observed interictally, generally while the infant is awake. Its appearance may precede or follow a cluster of spasms. A variety of EEG findings may be seen during spasms. Hrachovy and Frost have described several varia-tions, termed the modified hypsarrhythmias, which appear to occur more commonly than the classically described pattern." Transient alterations in the EEG occur throughout the day in most infants. The hypsarrhythmic pattern is most often seen in younger infants during the early stages of the disorder. With maturation, this chaotic EEG finding gives way to more organized patterns. More than half of the patients will have a normal EEG by age 8 years.IS There is a strong, but not exclusive, association between infantile spasms and hypsarrhythmia." Only rarely are infantile spasms observed in patients with a normal EEG; in such cases, the diagnosis should be questioned. Hypsarrhythmia is seen uncommonly in association with disorders other than infantile spasms. A suppression-burst hypsarrhythmia variant has been observed in newborns afflicted with early infantile epileptic encephalopathy or neonatal myelonic encephalopathy, but this is not believed to herald the onset of infantile spasms. I'
Epidemiology and Natural Course
Infantile spasm disorder is rare. The annual incidence rate of new cases is between 0.16 and 0.42 per 1000 live births. An estimated 643-1005 new cases are expected annually in the US, based on current statistics. The prevalence of this disorder has been reported to be 0.14-0.19 per 1000 children. It has been noted that the prevalence of infantile spasms, a measure of the number of cases in the population, is lower than the incidence, a measure of the number of new cases per year. This discrepancy is likely caused by the impact of mortality and the transformation of infantile spasms into other seizure disorders in later childhood. A slight, yet clear, male predominance exists, with the male:female ratio being 1.25: 1. There is no evidence of any racial or geographic tendencies."
Infantile spasm disorder is also age specific, with the peak onset of symptoms occurring between 2 and 8 months of age.4.IO.18.20 Although individual cases have been reported to occur in children as old as 6 years, approximately 85-90 percent of all reported cases have had the onset of spasms prior to 12 months." It has been argued that the onset of the disorder might be younger than that generally reported because the spasms may be very subtle and difficult to distinguish from normal behavior during the early stages of the disease.':" In fact, the average time from the recognized onset of symptoms to diagnosis has been 3.5 months.'
The spontaneous remission rate for infantile spasms is estimated to be 9 percent at six months and 25 percent at one year," Furthermore, approximately 50 percent of infants will be spasm free by 3 years of age and 90 percent will no longer experience spasms by age 5 years. IS,18 Unfortunately, over 50 percent of patients have concurrent seizure disorders or develop them in infancy or early childhood. 3,5.I1,I2,22 The most common seizure types reported in these infants are tonic, simple partial, tonic-clonic, atonic, and atypical absence.l-" An estimated 23-61 percent of patients with infantile spasms will subsequently develop Lennox-Gastaut syndrome, another age-specific epileptic syndrome characterized by intractable seizures." The longterm prognosis for normal mental development is relatively poor, but is markedly influenced by comorbidity and the child's neurologic status prior to the onset of spasms. A 
Treatment
Anticonvulsants, including phenobarbital, the hydantoins, carbamazepine, and the succinimides, have been ineffective in the management of infantile spasms. 3.4,11.21.22 Among the antiepileptic drugs, only the benzodiazepines,1l,40-42 valproic acid,43-48 and vigabatrin.f''" have shown any efficacy in reducing spasm frequency and severity. Sorel and Dusaucy-Bauloye were the first to report the effectiveness of ACTH, resulting in both cessation of spasms and disappearance of the hypsarrhythmic EEG finding," Hormonal therapy with ACTH and/or prednisone has been the most frequently studied treatment modality for infantile spasms and appears to be the most effective. Tables 2 and  3 summarize the results from studies of nonhormonal and hormonal treatments, respectively.
In the past, a ketogenic diet was advocated for the treatment of infantile spasms, but a relatively low response rate, poor tolerability and patient compliance, and its high cost have limited the usefulness of this modality.-" Other nontraditional agents, including pyridoxine,45.53.54 methy-hormone (ACTH) in some patients; thus, it seems implausible that neuronal maturation or neuronal repair could occur in such a brief time interval.
Baram has postulated that infantile spasms are the result of excess corticotropin-releasing hormone (CRH) activity during infancy," CRH is an excitatory neuropeptide whose potency is inversely related to age. In an animal model, CRH has been shown to be a potent convulsant in infancy, but its ability to provoke seizure activity diminishes rapidly with increasing age. The increased sensitivity to CRH in early life may be caused by a higher concentration of CRH receptors in the CNS during early postnatal development. According to this theory, abnormal CRH production, release, and response is the result of abnormal stress in early life or an aberrant response to common stresses. CNS injury from various insults (Table I ) may result in hypertrophy or sprouting of CRH-containing neuronal pathways. This theory would explain why infantile spasms appear in infancy, and why they eventually resolve with advancing age. It would also provide a plausible rationale as to why ACTH and glucocorticoids, which suppress CRH release, rapidly terminate spasms in many patients. The direct influence of hormones on seizures of various types and seizure vulnerability was reviewed in 1992. 39 poorer prognosis can be expected in infants who have developmental abnormalities prior to the appearance of infantile spasms.i-":"
Etiology and Pathophysiology
The precise etiology and pathophysiology of infantile spasms are not well understood. Given that infantile spasms become apparent at a specific stage of brain maturation, it has been hypothesized that a derangement in the normal development of the central nervous system (CNS) is most likely.5.B Numerous prenatal, perinatal, and postnatal disturbances of CNS function have been associated with infantile spasms (Table 1) . 3,4,11.12.17.24 However, no single factor has been identified as a fundamental pathophysiologic cause of this disorder. Indeed, no etiologic factor has been identified in approximately 40 percent of reported cases.
Immunizations, particularly the whole-cell pertussis vaccination, have been implicated as etiologic factors in the development of infantile spasms. Because vaccinations are given during the same time period as the peak onset of infantile spasms, it is difficult to determine whether the pertussis or the diphtheria-pertussis-tetanus (OPT) vaccines are causally related. Comprehensive, well-designed epidemiologic studies have failed to find a causal link between the pertussis vaccine and infantile spasms.P-" The current consensus is that the reported association between the pertussis/OPT vaccines and infantile spasms is coincidental. 27, 28 Spasms of no identifiable cause in infants whose development was normal prior to the onset of spasms are classified as idiopathic or cryptogenic, whereas those that have an identifiable cause are classified as syrnptomatic.v-" Following a careful history, physical examination, and radiologic studies, most spasms (>75 percent) are classified as symptomatic. I 1, 24 The classification of spasms as cryptogenic or symptomatic has considerable implications for long-term outcome and treatment. 5.6 • 18,29 Among infants with symptomatic spasms, normal mental development is attained in only 5-19 percent." Among infants with cryptogenic spasms, 30-70 percent develop normally and attain an intelligence quotient (IQ) >80. 18 Some case series have reported an improvement in cognitive development with the early use of hormonal therapy in patients with cryptogenic spasms.P'" The poorer prognosis for infants with symptomatic spasms is likely the result of the underlying neuropathology and does not appear to be altered by currently available drug treatments.
Several studies have suggested that the syndrome is associated with alterations in the monoaminergic, serotonergic, and gamma-aminobutyric acid (GABA)-minergic neurotransmitter systems.P-" It has been speculated that the spasms are a result of an imbalance in the concentrations of one or more neurotransmitters in critical cerebral pathways. Although valuable, these studies fail to elucidate the primary pathophysiologic defect causing the aberrations in neurotransmitter concentrations. To explain these findings, early theories hypothesized that the disorder might be the result of either failed neuron maturation or immunologically mediated damage to the CNS. 10,20,23,37 Although both theories have merit, several observations would make them unlikely explanations. Most notably, spasms can be ameliorated rapidly with a single dose of adrenocorticotrophic sergide and n-methylparatyrosine," and tetrabenazine,"
have shown little or no efficacy. Neurosurgery has shown much promise and may be the treatment of choice for select cases in which a localized CNS abnormality can be demonstrated.P''" In symptomatic cases, the treatment of the associated factors that may have contributed to the development of the disorder (Table 1) would seem a logical step toward ameliorating or reversing the disease. However, except in cases associated with a localized CNS lesion, few data are available to support this contention. Unfortunately, the research conducted to date with regard to the treatment of infantile spasms has been fraught with problems. Only two prospective, randomized, controlled clinical trials have been reported in the literature. 40 • 67 Confounding the results of most studies, investigators have allowed the concomitant use of other anticonvulsants. Furthermore, a myriad of drug dosages and treatment durations have been used. Because of the relative rarity of in-fantile spasms, it has been difficult to enroll a sufficient number of subjects to detect a difference in efficacy between treatment groups. Without placebo control groups, it is difficult to distinguish drug effect from the natural course of the disorder, which is characterized by a high rate of spontaneous remission.
The inherent difference in long-term prognosis for cryptogenic and symptomatic patients requires that separate analysis be undertaken for these distinct groups. Unfortunately, most studies have analyzed symptomatic and cryptogenic patients as a single group. With advances in medical imaging and a greater ability to detect an underlying cause for the disorder, the percentage of cases classified as cryptogenic has declined to less than 15 percent.v-" Thus, the results reported in older studies may no longer be applicable. Despite the ability of some therapies to ameliorate or abolish spasms, no drug has been proven to alter the long-term prognosis of this syndrome.v'-":" ACTH =adrenocorticotrophic hormone: NR =not reported: TRH =thyrotropin-releasing hormone. "Spasm control =75-100 percent reduction in spasm frequency except where noted.
BENZODIAZEPINES
Diazepam, nitrazepam, and clonazepam have all been reported to be effective to varying degrees in the treatment of infantile spasms.t-" Vasella et al. reported that 38 percent of clonazepam-treated infants had a substantial reduction in spasm activity, but this improvement could only be maintained for six months in 22 percent of patients." Given that the spontaneous remission rate for the disorder approaches 10 percent at six months," these data suggest only a minority of patients benefit from long-term clonazepam therapy.
Of the benzodiazepines, only nitrazepam has been studied in a prospective, randomized, blind, and controlled manner," In a multicenter study, Dreifuss et al. compared the efficacy of nitrazepam and ACTH in 52 infants with infantile spasms. Twenty-seven infants received nitrazepam 0.2 mg/kg/d bid initially and were titrated to a maximum of 2 mg/d. Based on response, the dosage of nitrazepam was increased twice weekly by increments of 0.3-0.4 mg/kg/d, as tolerated. The maintenance dosages of nitrazepam used in these infants ranged from 4.8 to 9.0 mg/d. Twenty-five infants received ACTH 40 unit/d im. The two groups were comparable with respect to baseline characteristics, including age and spasm frequency."
The results showed that after 4 weeks of treatment both nitrazepam and ACTH significantly (p::;0.05) reduced the mean spasm frequency compared with baseline. Nitraze pam reduced the mean number of spasms per 24 hours from 174.3 to 52.2. ACTH-treated infants experienced a similar reduction in mean spasm frequency, from 196.1 to 106.4. The percentage of infants who had an excellent response, defined as a 75 percent or greater reduction in spasm frequency from baseline, was also similar (52 percent for nitrazepam vs. 57 percent for ACTH). As might be expected, nitrazepam produced drowsiness (50 percent) and hypotonia (40 percent) in a substantial percentage of infants. Further, accumulation of respiratory tract secretions and excessive drooling occurred in 45 percent of nitrazepam-treated patients."
Although these data show nitrazepam to be effective in the short-term reduction of spasm frequency, there is no evidence that this benefit is maintained over time. Other data suggest that tolerance of the effects of benzodiazepines develops within a few months. 4 .23.4t Some have been critical of the Driefuss et al. study for using mean spasm frequency rather than cessation of spasms as their main ef-ficacy measure." In addition, the effect of nitrazepam on the interictal EEG activity was not evaluated. In summary, although benzodiazepines can reduce spasm frequency in the short term, the clinical usefulness of these agents in the treatment of infantile spasms appears limited, based on the scant data available.
VALPROIC ACID
The usefulness of valproic acid in the control of infantile spasms has been examined in several uncontrolled studies and case seriesY-48 Although the data are promising, none of the studies published in the literature to date have been blind or controlled therapeutic trials.
Pavone et al. reported their experience with valproic acid therapy in 18 infants with infantile spasms. All patients were given valproic acid 200 mg/mL oral solution dosed at 20 mg/kg/d administered in three equally divided doses. Within 20 days of therapy initiation, spasms were abolished in 4 patients. A good response, defined as a 50 percent or greater reduction in spasm frequency, was observed in 8 infants. The EEG normalized in the 4 infants whose spasms disappeared and was markedly improved in 5 other patients. The investigators stated a good correlation between EEG response and clinical response, but no statistical analysis was reported. Three infants who failed to show any response to valproic acid therapy were treated subsequently with ACTH. After 12-36 months of therapy, 16 of the 18 infants showed delayed psychomotor development and 7 children had residual seizures, including 6 who developed generalized tonic-clonic type seizures. Valproic acid serum concentrations were obtained in 8 infants and ranged from 40 to 80 ug/ml., The treatment was apparently well tolerated, with 1 infant becoming lethargic and developing hiccups when the dosage was increased to 30 mg/kg/d. These effects promptly abated when the dosage was decreased. Three infants experienced gastrointestinal disturbances during therapy initiation that did not necessitate drug discontinuation."
Bachman reported his experience with valproic acid therapy in 19 infants treated over a two-year period: 8 of the patients were treated with valproic acid only, 5 patients were initially treated with ACTH and when they failed to respond were given a trial of valproic acid, and 6 patients who experienced no improvement with valproic acid were subsequently treated with ACTH. Valproic acid therapy was initiated at 15-20 mg/kg/d. The dosage was titrated upward until either complete seizure control was achieved, adverse effects became evident, or a maximum dosage of 60 mg/kg/d was reached. Serum valproic acid concentrations were not reported. Overall, 8 patients (42 percent) had an excellent response to valproic acid therapy, with complete resolution of spasms. Additionally, 4 infants showed some modest improvement and 2 infants had worsening of spasms. Adverse effects from valproic acid were infrequent, with lethargy being the most common. One patient had severe gastrointestinal distress, elevated liver function enzymes, and prolonged prothrombin and partial thromboplastin times, necessitating drug discontinuation.f Siemes et al. conducted a prospective, unblinded, uncontrolled trial with valproic acid for the treatment of infantile spasms in 22 newly diagnosed and previously untreated infants. Patients were treated with an initial dose of valproic acid 15 mg/kg/d, given in three equally divided doses. The dosage was increased every other day by 10 mglkg/d increments until spasms were completely controlled or to a maximum dosage of 100 mglkg/d. After 4 weeks, if valproic acid therapy failed to reduce spasm frequency to less than 25 percent of baseline, dexamethasone was added. A thorough neurologic evaluation of each patient was performed at baseline and every 3 months thereafter. If a satisfactory treatment response to valproic acid was achieved and maintained for at least 3 months, the dosage was gradually reduced. The results show that valproic acid monotherapy induced complete cessation of spasms in II infants at 4 weeks and 15 infants at 6 weeks. Seventeen children achieved complete spasm control within the first 3 months of monotherapy; however, 3 infants experienced a return of spasms. At 6 months, 73 percent achieved complete spasm control with valproic acid monotherapy. Fifteen infants were followed for a period of 12 months or longer, with more than 70 percent remaining seizure-free on valproic acid monotherapy. Disappearance of hypsarrhythmia on EEG was observed in 73 percent of patients at 3 months and in 91 percent at 6 months. During the initial 3 months of therapy, the average daily dosage of valproic acid was 74 mg/kg/d (range 40-100) and average plasma concentration was 113 ug/ml, (range 46-177). The investigators were able to reduce the dosages in most infants, with the mean dosage and plasma concentration at 12 months being 46 mg/kg/d and 88 ug/ml., respectively. Gastrointestinal symptoms, lethargy, and hypotonia occurred frequently with valproic acid during the initial dose titration phase. Within the first 6 months of therapy, 7 children developed a transient thrombocytopenic purpura that resolved with dose reduction. One child also had a transient elevation of serum liver enzymes."
The evidence suggests that valproic acid can effectively control spasms in 40-70 percent of infants. Relatively high doses of valproic acid to achieve serum concentrations greater than 100 ug/rnl, may be necessary to abolish spasms in most patients. Gastrointestinal distress and lethargy are common, but these adverse effects usually appear only during dose titration and are transient." Valproic acid has been associated with a number of biochemical abnormalities, particularly hyperammonemia and altered carnitine metabolism.v-v Thrombocytopenia associated with high dosages may limit valproic acid therapy. By far the most serious and worrisome adverse effect of valproic acid is irreversible and fatal hepatotoxicity. The risk of val-Infantile Spasms proate-induced hepatotoxicity is substantial in children less than 2 years of age. The risk appears greatest in children who are mentally retarded, demonstrate developmental delay, or possess neurologic abnormalities, and who are treated with other antiepileptic drugs simultaneously with valproic acid. Fatal hepatotoxicity is estimated to occur in I in 500 infants less than 2 years old concomitantly treated with valproic acid and another anticonvulsant agent. When given as monotherapy in children less than 2 years of age, the risk of fatal hepatotoxicity induced by valproic acid is substantially less, estimated to occur in 1 in 7000. 63 No analysis has been made as to whether valproic acid positively affects the long-term cognitive development of these infants.
VIGABATRIN
Vigabatrin (gamma-vinyl GABA) has been the most recent antiepileptic agent to show promise in the treatment of infantile spasms. 49 • 52 In an open trial, Chiron et al. examined the efficacy of vigabatrin as add-on therapy to standard anticonvulsant regimens in 70 children with poorly controlled infantile spasms. All subjects had refractory spasms despite treatment with corticosteroids, carbamazepine, benzodiazepines, and/or valproic acid. The children ranged in age from 2 months to 13 years, although most were less than 2 years old. Thirty-seven patients had cryptogenic infantile spasms and 33 had symptomatic spasms. Most patients continued to receive one or more previously prescribed anticonvulsants (mean 1.7 drugs); only 4 patients had discontinued all previous drugs at study entry. Vigabatrin was added to each patient's preexisting drug regimen. The dosage of vigabatrin was initially 50-200 mg/kg/d administered in two equal doses. The dosage was titrated weekly on the basis of clinical response and tolerability. If spasm frequency was reduced by more than 50 percent during the initial 5-month evaluation phase, patients were allowed to continue vigabatrin therapy. During the maintenance phase of the study, discontinuation of concomitant anticonvulsants was attempted."
Two patients withdrew during dosage escalation because of intolerance to the drug. Details as to the nature of the drug intolerance were not provided. During the initial three months of therapy, a greater than 50 percent reduction in spasm frequency was achieved in 46 children (68 percent) and complete suppression of spasms occurred in 29 (43 percent). In patients with a complete response to therapy, the EEG hypsarrhythmia disappeared. Of children with symptomatic infantile spasms, 75 percent responded to vigabatrin compared with a 36 percent response rate in the cryptogenic group. Infants with tuberous sclerosis as the underlying etiology of their disorder responded best, with 12 of 14 (86 percent) showing a greater than 50 percent reduction in spasms and 10 of 14 (71 percent) a complete response. Patients in whom the duration of spasms was less than 12 months had a better response rate than infants who had spasms for more than 12 months (74 and 59 percent, respectively)."
Fifty-five patients entered the maintenance phase of this study. Spasm control was maintained in 85 percent of symptomatic patients during an 8-33 month follow-up period. The response was particularly striking in the tuberous sclerosis group, with 100 percent of patients achieving and maintaining remission of spasms. Among 27 infants with cryptogenic spasms who entered the maintenance phase of the study, only 12 maintained their initial response. Overall, vigabatrin was discontinued in 10 patients because of a loss of efficacy over time. Discontinuation of concomitant anticonvulsants was attempted in 30 patients with modest success. Only 8 infants were able to maintain spasm and seizure control when they were receiving vigabatrin as monotherapy."
Vigabatrin was well tolerated, as 74 percent of patients experienced no adverse effects. Sedation (7 percent), hypotonia (5.7 percent), and excitation (4 percent) were the most common adverse effects. Four children experienced excessive weight gain. Adverse events generally occurred during therapy initiation, with only 7 percent reporting any adverse effects after three months of vigabatrin therapy. No adverse effect was observed in any clinical laboratory parameter, including blood cell counts, renal function, and liver function. Vigabatrin did not alter the serum concentrations of concomitantly administered anticonvulsants. No measurement of serum vigabatrin concentrations was reported." In an unblinded, uncontrolled trial, Appleton and Montiel-Viesca reported their experience with vigabatrin monotherapy for infantile spasms in 15 infants. Vigabatrin therapy was initiated upon diagnosis, prior to any other anticonvulsant or hormonal therapy, at a dosage of 50-80 mglkg/d and titrated over 3 days to a maximum dosage of 100-150 mg/kg/d. If a patient did not respond to vigabatrin therapy within 5 days of therapy initiation, alternative therapy was substituted. Eleven patients had a greater than 75 percent reduction in spasm frequency within 72 hours of therapy initiation. Although 7 of these infants experienced a relapse after 4-6 months of therapy, only I infant had a complete relapse with difficult to control spasms despite dosage escalation. Four infants attained complete and sustained spasm control with no other seizure types developing during a 3-20 month follow-up period. Four other infants did not respond to vigabatrin therapy and alternative agents were of limited benefit. The investigators concluded that vigabatrin monotherapy is effective in the majority of infants within 72 hours and that a short delay in the initiation of hormonal therapy would not adversely affect outcome. 52 Although these reports are encouraging, a blind, controlled trial is needed to best evaluate the role of vigabatrin in the treatment of infantile spasms. The efficacy of vigabatrin at different ages was not reported; therefore, it is not known whether the higher response rate seen in Chiron et al.'s study in infants with spasms for less than 12months is an age-specific phenomenon. This observation in light of Appleton and Montiel-Viesca's data would suggest that vigabatrin may be most effective when given as initial treatment soon after the onset of symptoms. No evaluation of the impact of vigabatrin on long-term cognitive function has been made. Given that the spontaneous remission rate is reported to be 9-25 percent after I year, it is unlikely that the rate of response (43-73 percent) observed within a few days of treatment initiation can be explained by the natural course of the illness. The high rate of reponse observed in these reports, involving patients refractory to other treatments and previously untreated patients, compares favorably with the results from prospective trials of hormonal therapy and merits further research.
HORMONAL THERAPY
Following the first report of the dramatic benefit of ACTH to terminate infantile spasms, studies and case series have repeatedly confirmed the effectiveness of hormonal therapy.3.4·8. 9.12.22.24.64.71 Hormonal therapy has been shown to be efficacious in controlling spasms, achieving complete remission in 50-75 percent of infants within 2-4 weeks of initiation. Opinions differ as to the relative efficacy of ACTH and prednisone. Some investigators believe ACTH and prednisone to be therapeutically equivalent, but others consider ACTH superior. Furthermore, some investigators suggest that ACTH in high dosages (dosages >40 units/d) and/or for prolonged durations (>2 mo) produces substantially greater spasm control than lower ACTH dosages given over shorter periods. Some contend that ACTH works through a mechanism other than stimulation of cortisol secretion, instead acting directly on brain tissue to terminate infantile spasms. 64 .72.73 In addition, some believe that ACTH can improve the long-term developmental status of these infants. Unfortunately, conclusive evidence is not available to support any of these opinions.
In the best designed clinical trial conducted to date evaluating the efficacy of hormonal therapy, Hrachovy et al. failed to demonstrate a significant difference between ACTH and prednisone. In this double-blind, randomized, crossover design study, 24 infants with infantile spasms and confirmed hypsarrhythmia on EEG were treated with ACTH or prednisone. Many patients had previously been treated with anticonvulsants, but none had received ACTH or corticosteroids prior to entry into the study. Response to therapy was defined as a total cessation of spasms and disappearance of hypsarrhythmia. After baseline monitoring, patients were randomly assigned to receive a two-week regimen of either ACTH gel 20 units/d im and prednisone placebo or prednisone 2 mglkg/d and an ACTH gel placebo. If the patient responded within two weeks, the dosage of the drug was tapered and discontinued over one week. If the patient did not respond, therapy was continued for four additional weeks (the ACTH dosage was increased to 30 units/d im) and then discontinued in a two-week taper. Nonresponders were then crossed over to the other drug following a one-week wash-out period."
The overall rate of response to ACTH (75 percent) and prednisone (58 percent) was not statistically different. Of those who did not respond to ACTH therapy, 43 percent subsequently responded to prednisone in the crossover phase of the study; 50% of those who did not respond to prednisone therapy responded to ACTH. Most patients who responded to either ACTH or prednisone did so within two weeks of therapy initiation. Thirty-one percent of responders had a recurrence of spasm during the six-week follow-up period. No responder had a return of a hypsarrhythmic EEG pattern. A second course of therapy was effective in most relapsing patients."
Glaze et al. reported the long-term outcome of 64 infants treated with either ACTH or prednisone who had been enrolled in three previously reported prospective studies. 67,69.74.75 Long-term outcome did not" differ between the ACTH and prednisone treatment responder groups. Only 3 of 13 prednisone responders and 2 of 24 ACTH responders showed normal or only mildly impaired cognitive development. Additionally, long-term development did not differ between treatment responders and nonre-sponders. Early treatment, defined as initiation of therapy within five weeks of onset of infantile spasms, did not influence outcome. As had been observed in other studies, a substantial difference in developmental outcome was seen between patients with cryptogenic and those with symptomatic spasms. It must be noted that the number of infants with cryptogenic spasms was small and the overall poor outcome observed in this study may be related to the high percentage (88 percent) of patients enrolled with symptomatic spasms." In contrast to Hrachovy et al. 'S67 findings and opinions, other investigators contend that early treatment with ACTH is superior to late treatment,18,30,41 that ACTH is superior to prednisone," and that high-dose ACTH is superior to low dose. 31,70.71 Singer et al. retrospectively reviewed the records of 55 children with infantile spasms treated between 1961 and 1974. Patients were given ACTH 40 units/d im for two weeks during an initial hospitalization and then 80 units im every other day for a minimum of three months. If the patient responded, ACTH was discontinued gradually over one month. If spasms or EEG findings recurred, ACTH was restarted at 80 units im every other day. All patients in this series received concomitant anticonvulsant therapy, most commonly phenobarbital. Overall, 76 percent of these infants achieved complete control of spasms at one year and 71 percent remained spasm free at three years. However, infants who were treated within one month of the onset of symptoms (31 patients) achieved a more rapid and sustained response compared with those treated more than one month after onset (24 patients). At two months, 55 percent of the early-treatment group were spasm free versus 8 percent in the late-treatment group. At six months, 87 percent of early-versus 58 percent of latetreated patients were spasm free. This difference was sustained at one-and three-year time points. Unfortunately, neither a comparison between the early-and late-treatment groups as to the relative percentage of patients with cryptogenic spasms or other possible confounding variables was made, nor was an assessment of the long-term developmental outcome made."
Lerman and Kivity reported their observations with 25 "primary" cases of infantile spasms from 1960 to 1978 treated with ACTH or cosyntropin, a long-acting synthetic corticotropin. Most patients also received a tapering regimen of prednisone for 6 months following the initial treatment with either ACTH or cosyntropin. Primary infantile spasms were defined as the absence of neurologic abnormalities prior to the onset of infantile spasms. Total cessation of spasms was achieved in 88 percent of these patients within 33 days of therapy initiation. The investigators also reported that all patients treated early, within I month of onset of symptoms, and 'adequately' had complete cessation of spasms, did not relapse following treatment, and achieved a normal intellectual capacity. Adequate treatment was defined as a dosage of ACTH of greater than 80 units/d im for 12 weeks or cosyntropin 1 mg three times weekly for 2 weeks and then tapered over 10 weeks. Regardless of dosage or duration of therapy, patients treated early had normal intellectual development in 85 percent of the cases versus only 25 percent in those treated late. No comparison of the early-versus late-treatment groups was made for confounding variables, such as intellectual capacity prior to treatment. Furthermore, the time interval fol-Infantile Spasms lowing treatment at which intellectual development was assessed was not defined by the authors."
Lombroso performed a comparative evaluation of 286 infants with infantile spasms treated with different protocols from 1958 to 1976 at the Boston Children's Hospital. Of these infants, 165 had symptomatic, and 121 cryptogenic infantile spasms. Seventy-two infants received no hormonal therapy and were treated with either a benzodiazepine, phenobarbital, phenytoin, or valproic acid alone. Thirty-nine symptomatic and 38 cryptogenic infants received prednisone 2 mglkg/d for 8 weeks and were tapered to I mglkg/d for 12-24 additional weeks. Sixty-nine symptomatic and 59 cryptogenic infants received an ACTH protocol: 110 units/mvd for 3 weeks, 70 units/msd for 2 weeks, and then 50 units/mvd on alternate days for 3 weeks. The concomitant use of traditional anticonvulsants was permitted with hormonal therapy. Nine infants died prior to the IO-month evaluation point."
Lombroso showed ACTH and prednisone to be equivalent at 10 months following the initiation of therapy for the entire cohort, with 75 vs. 62 percent, respectively, showing a greater than 50 percent improvement in spasm frequency. However, ACTH was superior in ameliorating seizure activity and normalizing EEG findings in the cryptogenic subpopulation. In cryptogenic patients, a significant (p<O.05) reduction in spasms was seen in 86 percent of ACTHtreated patients compared with 68 percent of the prednisone-treated group,"
Lombroso also analyzed the long-term outcome in 53 patients with cryptogenic spasms, including 17 prednisoneand 36 ACTH-treated infants. After 6 years, a greater percentage of the ACTH-treated group than the prednisonetreated group remained seizure free (62 vs. 29 percent, respectively) and attained normal intelligence (IQ >80; 50 vs. 12 percent, respectively). These differences reached statistical significance (p<0.05). Early treatment with ACTH, defined as treatment within one month of onset of infantile spasms, also improved the long-term prognosis for patients with cryptogenic spasms. Normal intellectual development was attained in 52 percent of those treated early as compared with 27 percent of those treated late. Early-treated patients were also more likely to be seizure free at 6 years than their late-treatment counterparts (67 vs. 33 percent, respectively). Based on these findings, Lombroso concluded that early treatment with ACTH in patients with cryptogenic spasms can optimize the potential for long-term spasm control and intellectual development." Snead et al. achieved remarkable results in 15 infants treated with high dosages of ACTH (150 units/mvd). Most of these infants (14) had symptomatic spasms and had neurologic abnormalities prior to the onset of infantile spasms. The ACTH dosage was 75 units/m' im bid for one week, then 75 units/mvd for one week, and then 75 units/mevery other day for one week, followed by a nine-week taper. Twelve patients had complete cessation of spasms within seven days of initiating ACTH therapy, and 2 additional patients achieved complete control within three weeks. Only one patient, who had intractable seizures of multiple types, did not respond to this regimen. Two patients had a relapse of infantile spasms after completion of their treatment regimen. Recurrent spasms were recontrolled with a second course of ACTH therapy. Long-term follow-up results were not reported." Ito et al. reviewed the case histories of 41 infants treated from 1977 to 1986 who had received various dosages of ACTH. The investigators reported improved spasm control with dosages of ACTH >0.6 units/kg/d. There was an improvement in developmental outcome in infants treated with daily dosages of> 1.6 units/kg/d and cumulative dosages of >44 units/kg. Many of these children also received concomitant antiepileptic drugs. No comparison of confounding variables was made between the low-and highdose ACTH treatment groups." Because these findings are derived from a retrospective analysis of the data, the validity of the conclusions is questionable.
Pollack et aI. retrospectively reviewed the long-term outcomes of 18 infants who had initially responded to ACTH between 1961 and 1974. These infants were treated with up to 40 units of ACTH for 5 weeks. Modal age at the last follow-up visit was 5 years (range 15 mo to 16 y). Five patients had cryptogenic spasms. The average interval between onset of spasms and ACTH treatment was 5 weeks (range 2-15 wk). During follow-up, infantile spasms recurred or other seizures appeared in most patients, despite the continued use of standard anticonvulsants. Only 8 of 18 (44 percent) of these infants remained free of seizures or spasms. Furthermore, only 4 (22 percent) were seizure free and without intellectual impairment. All 4 of these infants had cryptogenic spasms. One of these 4 patients was lost to follow-up at 15 months of age." These data confirm previous observations that despite an adequate initial response to treatment, the majority of symptomatic infants will have intellectual deficits, as well as subsequent spasm or seizure activity.
In a provocative study, Matsumoto et al. compared the efficacy of ACTH with thyrotropin-releasing hormone (TRH), which is thought to possess some neuromodulatory activity unrelated to its endocrinologic effects. These investigators treated 64 infants with intractable seizures, including 33 infants with infantile spasms. A synthetic ACTH was administered in a dose of O. 125-0.75 mg (equivalent to 5-30 units of natural ACTH) im once daily for 1-4 weeks to 20 children with infantile spasms. A single daily 0.5-1.0 mg im dose of TRH-tartrates (TRH-t) was administered to 13 subjects with infantile spasms for 1-4 weeks. Any previously administered anticonvulsants were continued during the treatment and follow-up periods. The TRHtreated group was substantially older (mean 5.0 vs. 2.75 y) and followed for a shorter period of time (mean 8 mo vs. 3.0 y). In the TRH treatment group, 7 patients (53.8 percent) achieved complete spasm remission within 16 days of therapy initiation. This compared favorably with ACTH, as 15 of 20 patients (75.0 percent) had cessation of infantile spasms. However, the hypsarrhythmia did not respond as markedly with TRH treatment. Only 23 percent of TRH-treated patients had a marked improvement in the EEG findings compared with 60 percent of infants treated with ACTH. Relapse of spasms occurred within 3 months in 4 of the 7 patients who initially responded to TRH. Of the 6 patients who did not respond to TRH, 5 promptly responded to ACTH treatment. Although an interesting therapeutic intervention with potential given its apparent limited benefit, TRH should be used only in patients in whom more conventional treatments have failed." Hormonal therapy with ACTH or glucocorticoids is not without risks.":" Although some investigators report low rates of adverse effects,31,32,68.69 Riikonen and Donner report 37 percent of children treated with ACTH experience druginduced morbidity or mortality." The most common serious complications of ACTH therapy are septicemia, pneumonia, and urinary and gastrointestinal tract infections. Pneumocystis carinii pneumonia has also been reported. 43.81 Systolic hypertension has occurred in 19-32 percent of infants treated with ACTH.4.20 Hypertrophic cardiomyopathy with long-term hormonal treatment has become an increasingly recognized problem.v" A few investigators have reported deaths presumed secondary to or facilitated by hormonal therapy. 19.43.78 Less serious adverse effects, including cushingoid features, hirsutism, irritability, and sleep disturbances, have been reported in as many as 85 percent of ACTH-or prednisone-treated infants." The incidence and severity of adverse effects appear to be related to dosage. 59.78 ACTH and prednisone can transiently shrink brain tissue, increasing subarachnoid space and ventricular size, and thus make computed tomography or magnetic resonance imaging evaluation following the initiation of therapy difficult."
Summary
Infantile spasm disorder constitutes an uncommon syndrome with a poor long-term prognosis for normal intellectual development. Standard anticonvulsants, including phenytoin, carbamazepine, and phenobarbital, have little effect on spasm frequency. Benzodiazepines, particularly nitrazepam, have been shown to ameliorate spasms on a short-term basis, but tolerance appears to develop. In infants who are unable to tolerate hormonal therapy, valproic acid is a reasonable alternative, achieving complete spasm control in more than 40 percent of children. However, relatively large dosages must be used to effectively control spasms in many infants. Furthermore, the relatively high risk of fatal hepatotoxicity induced by valproic acid is of concern in this patient population. Vigabatrin has shown promise for the treatment of infantile spasms, but further study is needed.
The body of evidence published to date supports the use of hormonal therapy, either ACTH or prednisone, as the preferred agents to control infantile spasms. Termination of spasms can be achieved in 50-75 percent of hormonally treated infants. The only blind, prospective trial of lowdose ACTH compared with prednisone failed to demonstrate a significant difference in short-or long-term outcomes. However, the number of patients enrolled in this study may not have been sufficient to detect a clinically important difference in response. The cumulative evidence from several retrospective studies suggests that ACTH may be superior to prednisone. Infants who do not respond to ACTH, however, often respond to prednisone, and vice versa. Response to hormonal therapy usually occurs within two to four weeks of initiation of treatment, with complete cessation of spasms and disappearance of hypsarrhythmia on the EEG. Response is frequently maintained for months to years after discontinuation of ACTH or prednisone. Infants who relapse following drug discontinuation generally respond to a second course of hormonal therapy. There is some evidence that ACTH in high dosages (~80 units/d or 150 units/mvd) produces a slightly greater response, more rapidly. ACTH may exert direct activity on nerve tissue apart from its indirect activity via increased cortisol secretion.
Prognosis for normal development appears to depend primarily upon whether an infant has cryptogenic or symptomatic spasms. If ACTH has any impact on altering the long-term outcome of this syndrome, early treatment, initiated within one month of onset of symptoms, may be critical. Any potential to improve long-term outcomes with drug treatment likely exists only for infants with cryptogenic spasms. No drug therapy is likely to alter the poor prognosis for patients with symptomatic spasms, given the existing neurologic damage. Unfortunately, the evidence to date is insufficient to support conclusively the contention that ACTH, given early and in high doses, can improve the prognosis for normal cognitive development in these infants.
Although effective for infantile spasms, ACTH and glucocorticoids have several potential serious adverse effects, particularly with higher doses, including an increased risk of infection, hypertension, hypertrophic cardiomyopathy, and electrolyte disturbances. Thus, close patient monitoring is required. Alternate daily dosing and drug holidays, while potentially attractive dosing options commonly used to reduce the risk of adverse effects associated with chronic steroid use, have not been studied in this patient population. The effectiveness of alternative steroid dosing regimens to reduce or eliminate spasms can only be speculated upon. Although ACTH may be preferable for many patients, it must be given by intramuscular injection and thus requires parental education for its proper administration. Prednisone has the advantage of being available in an oral liquid formulation. Well-designed, blind, controlled clinical trials are needed to definitively answer many lingering questions regarding the treatment of infantile spasms.e-ConceptslLife Sciences" como tarnbienbibliograffas de artfculos relevantes. SELECCION DE ESTUDIOS: Todas las publicaciones originales y repasos identificados acerca de los razgos clinicos. epidemiologfa, etiologfa, patofisiologfa, y tratamiento de espasmos infantiles fueron revisados. EI enfasis fue hecho en estudios originales publicados desde 1975. EXTRACCION DE DATOS: Datos de investigaciones publicados fueron extrafdos por los autores y evaluados de acuerdo al diserio del estudio, tamafio de muestra, regfrnenes de dosificaci6n, medidas de los resultados, y tratamiento seguro y eficaz. SINTESIS DE DATOS: Los espasmos infantiles es un raro sfndrome epileptico con un pobre progn6stico a largo plazo para un desarrollo intelectual normal. Los espasmos son caracterizados por una breve contracci6n sirnetrica de los rmisculos del cuello, tronco, y/o extremidades, frecuentemente ocurren en series de 2 y no mas de 100 espasmos durante un episodio. Este desorden es especffico a la edad, con un pico al comenzar los sfntornas ocurriendo entre 2 a 8 meses de edad. Los infantes con causa no identificable y desarrollo normal antes del inicio del espasmo infantil son c1asificados como criptogenico 0 ideopatico; mientras que aquellos con causa identificable son c1asificados como sintomatico, EI progn6stico a largo plazo es mejer para los casos criptogenico con un 30-70 por ciento asociado al intelecto normal comparado con un 5-19 por ciento en casos sintomaticos. La etiologia y patofisiologfa no esta bien c1aros. Las teorfas mas recientes postulan que los espasmos infantiles podrfan ser debido a excesos en la actividad de liberaci6n de hormona corticotropina durante la infancia. La asociaci6n sospechada entre la vacuna de pertusis de celula completa y espasmos infantiles es coincidencia. Pocos ensayos bien disefiados y prospectivos para el tratamiento de espasmos infantiles han sido realizados. Los anticonvulsantes regulares como fenitofn, barbituratos, carbamazxepina y los sucimidas son inefectivos. Entre los anticonvulsantes, solo las benzodiazepinas, el acido valproico y vigabatrina han demostrado ser eficaz en reducir la frecuencia y severidad. La terapia hormonal con la hormona adrenocorticotr6pica (ACTH) y/o prednisona han sido el tratamiento de modalidad mas frecuentemente estudiado y parece ser el mas eficaz. La terapia hormonal logro completar el control de espasrno en un 50-75 por ciento de los infantesdentro de las primeras4 semanas de inicio. Las opinionesdifierenen cuanto la eficacia relativa entre el ACTH y prednisona, la necesidadde iniciar temprano el tratamiento hormonal,y los beneficiosde altas dosis de ACTH (>40 uJdfa). No hay tratarniento que demuestre mejorar el desarrollo intelectual a largo plazo de los infantes. La neurocirugfa podrfaser el tratamientode seleccionen algunoscasos cuando la anormalidadde CNS es localizada. Ensayos clfnicos prospectivos, bien diseiiadosy ciegos son necesariospara contestardefinitivamente muchas preguntas acerca del tratamientoen espasmos infantiles. 
